Education
About Us
Working with TipRanks
Follow Us
XWELL (XWEL)
NASDAQ:XWEL
Top Page
XWELL
(NASDAQ:XWEL)
Rating:47Neutral
Price Target:
$1.00
▼(-10.71%Downside)
XWELL (XWEL) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.89M
Dividend YieldN/A
Average Volume (3M)43.82K
Price to Earnings (P/E)―
Beta (1Y)0.84
Revenue Growth1.33%
EPS Growth35.82%
CountryUS
Employees246
SectorHealthcare
Sector Strength41
IndustryPersonal Products & Services
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,261,024
10 Day Avg. Volume32,863
30 Day Avg. Volume43,817
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)-1.03
Price to Sales (P/S)0.00
P/FCF Ratio-0.40
Enterprise Value/Market Cap1.98
Enterprise Value/Revenue0.09
Enterprise Value/Gross Profit1.54
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$1.00Price Target Upside-10.71% Downside
Rating ConsensusHold
Number of Analyst Covering0
XWELL Business Overview & Revenue Model
Company DescriptionXWELL (XWEL) is a company operating in the wellness and health sectors, focusing on delivering premium services and products to enhance customer well-being. The company offers a range of services including spa treatments, wellness products, and other health-related services aimed at improving customer experiences in various environments, particularly in airports and travel hubs.
How the Company Makes MoneyXWELL makes money through a diversified revenue model primarily centered around service fees from spa and wellness treatments offered in airports and other travel locations. Additionally, the company earns income from the sale of wellness products and retail items available at its locations. XWELL also capitalizes on partnerships with airports and other travel-related businesses to secure prime locations for its services, enhancing visibility and accessibility to travelers. These partnerships often involve revenue-sharing agreements or lease arrangements that contribute to the company's earnings.
XWELL Earnings Call Summary
Earnings Call Date:May 20, 2025
(Q3-2024)
| % Change Since: 21.74%|
Next Earnings Date:Nov 12, 2025
Earnings Call Sentiment Positive
The earnings call highlighted significant progress in revenue growth, strategic market expansion, and cost reductions, with improved financial metrics compared to the previous year. However, there were challenges such as increased salaries and legal expenses. Overall, the positive aspects and strategic advancements outweigh the negatives.Q3-2024 Updates
Positive Updates
Revenue Growth
Total revenue for Q3 2024 was approximately $8.4 million, up from $7.5 million in the prior year period.
Strategic Expansion Plans
Planning to expand into several attractive markets in Florida, with up to 10 XWELL properties expected by mid-2025. Opening first Naples Wax location in November 2024.
Successful Cost Reduction
Reduced total operating expenses by approximately 35% for the 9-month period in 2024 compared to the same period in 2023.
Decrease in Operating Loss
Operating loss for Q3 2024 was $4.8 million, a significant improvement from an operating loss of $12.1 million in the prior year third quarter.
Solid Financial Position
No long-term debt with cash and cash equivalents at $4.4 million and $11.7 million in marketable securities.
Positive Customer Engagement
Customer traction and foot traffic at the new Philadelphia International Airport XpresSpa have been solid, with promising performance from tech-forward installations.
Negative Updates
Increased Salaries and Benefits
Salaries and benefits were approximately $1.9 million in Q3 2024, compared to $1.2 million in the same period in 2023.
Legal Expenses Impact
General and administrative expenses were approximately $4.5 million, including over $2 million related to extraordinary legal expenses.
Company Guidance
During the XWELL Q3 2024 earnings call, several key metrics and strategic initiatives were highlighted. Total revenue for the quarter was approximately $8.4 million, a notable increase from $7.5 million in the same period last year. Revenue sources included $4.9 million from XpresSpa and Treat locations, $3.1 million from XpresTest, and $0.4 million from Naples Wax Center. Operating expenses significantly decreased to $6.8 million from $13.2 million in Q3 2023, contributing to a reduced operating loss of $4.8 million compared to $12.1 million the previous year. The company has also made strides in cost management, with a 35% reduction in total operating expenses over the first nine months of 2024 compared to the same period in 2023. XWELL is focusing on expanding its market presence, particularly in Florida, and is set to open new locations, including its first Naples Wax location and a spa at Penn Station. The company maintains a solid liquidity position with $4.4 million in cash and $11.7 million in marketable securities, with no long-term debt.XWELL Financial Statement Overview
Summary
XWELL is facing significant financial challenges, with deteriorating revenue and profitability metrics. The balance sheet shows weakened financial health with negative equity, and cash flow issues persist, reflecting operational inefficiencies and liquidity concerns. The company is under financial distress, requiring strategic adjustments to improve its financial position.Income Statement
The company's revenue has decreased significantly over the years, with a notable decline from 2021 to 2023. Gross profit margin improved slightly in 2023 compared to 2022, but remains weak at 26.3%. Net profit margin is negative, indicating consistent losses. EBIT and EBITDA margins are also negative, reflecting operational challenges despite some improvement in EBIT in 2024.35
Negative
Balance Sheet
The company has a negative stockholders' equity in 2024, indicating financial distress. The debt-to-equity ratio is not meaningful due to negative equity. The equity ratio is also negative, signaling potential solvency issues. Total assets have decreased significantly, impacting the company's financial stability.30
Negative
Cash Flow
Operating cash flow is negative, indicating cash outflows from operations. Free cash flow is also negative, reflecting ongoing financial strain. Cash flow from financing activities has been inconsistent, with a significant drop in 2024. The operating cash flow to net income ratio suggests poor cash generation relative to net income.28
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 33.90M | 30.11M | 55.94M | 73.73M | 8.38M |
| Gross Profit | 8.92M | 3.68M | 12.05M | 32.43M | -3.60M |
| EBITDA | -15.96M | -15.75M | -19.12M | 7.87M | -19.54M |
| Net Income | -16.85M | -27.74M | -32.63M | 3.35M | -92.23M |
Balance Sheet | |||||
| Total Assets | 25.35M | 38.99M | 70.43M | 127.27M | 103.13M |
| Cash, Cash Equivalents and Short-Term Investments | 11.80M | 23.05M | 42.19M | 105.51M | 89.80M |
| Total Debt | 10.77M | 11.09M | 14.11M | 13.82M | 15.38M |
| Total Liabilities | 17.61M | 18.02M | 22.48M | 27.33M | 22.76M |
| Stockholders Equity | -788.00K | 13.00M | 39.93M | 92.73M | 77.81M |
Cash Flow | |||||
| Free Cash Flow | -12.80M | -18.45M | -31.02M | 6.97M | -29.36M |
| Operating Cash Flow | -11.01M | -16.07M | -24.19M | 15.64M | -25.01M |
| Investing Cash Flow | 5.89M | 5.65M | -34.84M | -6.24M | -4.35M |
| Financing Cash Flow | 1.36M | 8.00K | -27.38M | 6.35M | 117.22M |
XWELL Technical Analysis
Neutral
1.12
Price Trends
0.97
Positive
0.94
Positive
1.20
Negative
Market Momentum
0.07
Negative
56.30
Neutral
47.81
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For XWEL, the sentiment is Neutral. The current price of 1.12 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 0.97, and below the 200-day MA of 1.20, indicating a neutral trend. The MACD of 0.07 indicates Negative momentum. The RSI at 56.30 is Neutral, neither overbought nor oversold. The STOCH value of 47.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for XWEL.
XWELL Risk Analysis
XWELL disclosed 52 risk factors in its most recent earnings report. XWELL reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
XWELL Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $49.50M | 0.54 | 548.07% | ― | -4.88% | ― | |
58 Neutral | $163.77M | 66.49 | -3.32% | ― | -39.47% | -110.28% | |
56 Neutral | $10.43M | 7.50 | 23.48% | ― | 12.93% | 66.81% | |
54 Neutral | $8.50M | ― | -446.50% | ― | 445.72% | 84.92% | |
52 Neutral | $7.63B | 0.11 | -62.96% | 2.08% | 16.16% | 0.31% | |
47 Neutral | $5.89M | ― | -797.66% | ― | 1.33% | 35.82% |
* Healthcare Sector Average
Performance Comparison
XWEL
XWELL
1.12
-0.89
-44.28%
MED
Medifast
14.90
-5.79
-27.98%
RGS
Regis
20.32
-10.85
-34.81%
MRM
MEDIROM Healthcare Technologies
1.32
-2.65
-66.75%
TRNR
Interactive Strength Inc
6.03
-694.97
-99.14%
XWELL Corporate Events
Shareholder MeetingsBusiness Operations and Strategy
XWELL Amends Bylaws to Alter Voting Requirements
Neutral
Jul 25, 2025
On July 24, 2025, XWELL, Inc. amended its bylaws to change the voting requirements for stockholder decisions. The amendment lowers the required stockholder vote for matters other than director elections to a majority of votes cast, excluding abstentions and broker non-votes, potentially impacting the company’s decision-making process and shareholder influence.
Delistings and Listing ChangesRegulatory Filings and Compliance
XWELL Faces Nasdaq Delisting Risk Over Bid Price
Negative
May 19, 2025
On May 13, 2025, XWELL, Inc. received a notification from the Nasdaq Stock Market indicating that the company’s common stock did not meet the minimum bid price requirement of $1.00 per share over a 30-day period, which is necessary for continued listing on the Nasdaq Capital Market. XWELL has been given a compliance period until November 10, 2025, to meet this requirement by maintaining a minimum closing bid price of $1.00 for at least ten consecutive business days. If XWELL fails to comply within this period, they may qualify for an additional 180-day extension if they meet other listing standards and provide a plan to address the deficiency, potentially through a reverse stock split. The letter does not immediately affect the company’s stock listing, which remains active on Nasdaq.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.